Everolimus

Generic Name: Everolimus

Brand Names: Afinitor, Votubia, Zortress

Drug Type: Small Molecule

Chemical Formula: C_₅₃H_₈₃NO_₁₄

CAS Number: 159351-69-6

Unique Ingredient Identifier: 9HW64Q8G6G

Background: Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Indication: Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...

Associated Conditions: Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors

Associated Therapies: -

Clinical Trials

CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma

Phase 3

Conditions: Renal Cell Cancer Metastatic

Interventions: Drug: CM082 combined with everolimus
Drug: CM082
Drug: Everolimus

First Posted Date: 2017-03-29

Last Posted Date: 2021-02-08

Lead Sponsor: AnewPharma

Target Recruit Count: 390

Registration Number: NCT03095040

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

Phase 2

Completed

Conditions: Neuroendocrine Tumors

Interventions: Drug: LEE011
Drug: everolimus

First Posted Date: 2017-03-03

Last Posted Date: 2024-10-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 21

Registration Number: NCT03070301

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Md Anderson Cancer Center, Houston, Texas, United States

and more 2 locations

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Phase 1

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
ERBB4 Gene Mutation
Refractory Malignant Solid Neoplasm
ERBB3 Gene Mutation
KRAS Gene Mutation
ERBB2 Gene Mutation
EGFR Gene Mutation
ERBB2 Gene Amplification
Metastatic Malignant Solid Neoplasm
EGFR Gene Amplification

Interventions: Drug: Everolimus
Drug: Neratinib
Drug: Palbociclib
Drug: Trametinib

First Posted Date: 2017-02-27

Last Posted Date: 2024-06-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 93

Registration Number: NCT03065387

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

Phase 3

Active, not recruiting

Conditions: Neuroendocrine Tumors

Interventions: Drug: 177Lu-edotreotide PRRT
Drug: Everolimus
Other: Amino-Acid Solution

First Posted Date: 2017-02-09

Last Posted Date: 2023-11-30

Lead Sponsor: ITM Solucin GmbH

Target Recruit Count: 309

Registration Number: NCT03049189

Locations: 🇦🇹
Allgemeines Krankenhaus Wien, Wien, Austria
🇵🇱
"Gammed" Izabela Chuchrowksa, Warsaw, Poland
🇨🇭
Inselspital, Universitätsspital Bern, Bern, Switzerland

and more 49 locations